Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2024-03-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于对会计师事务所2023年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (立信会计师事务所) for the 2023 audit of 天津瑞普生物技术股份有限公司. It details the auditor's qualifications, audit quality management, work plans, resources, and risk management related to the audit engagement. It is not the audit report itself but an assessment of the auditor's performance and compliance with professional standards. The document is relatively short (2482 characters) and focuses on audit quality evaluation rather than presenting financial statements or audit results. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related audit quality evaluations, excluding full annual reports. FY 2023
2024-03-29 Chinese
保定市收骏科技有限公司2023年度审计报告及财务报表
Audit Report / Information Classification · 100% confidence The document is titled '审计报告及财务报表' which translates to 'Audit Report and Financial Statements' for the fiscal year 2023 (January 1, 2023 to December 31, 2023). It contains detailed financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, statements of changes in equity, and extensive notes to the financial statements. The document includes an auditor's opinion section, basis for the opinion, management's responsibility, and auditor's responsibilities, consistent with a formal audit report. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document is a standalone Audit Report and Financial Statements filing, not a full Annual Report (10-K) or other category. The presence of the audit opinion and detailed financial statements aligns with the Audit Report / Information (AR) category. FY 2023
2024-03-29 Chinese
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 Annual Report Summary" of Tianjin Ringpu Bio-technology Co., Ltd. It contains detailed financial data for the year 2023, including total assets, net profit, revenue, quarterly financial data, shareholder information, and business overview. It also includes auditor's opinion and mentions the full annual report is available on the regulatory media. The document length is over 12,000 characters, indicating it is a substantive report, not just an announcement. The content matches the characteristics of an official yearly report covering company activity and full financial performance, which corresponds to an Annual Report (10-K) filing type. FY 2023
2024-03-29 Chinese
独立董事2023年度述职报告（才学鹏）
Management Reports Classification · 95% confidence The document is titled '独立董事2023 年度述职报告' which translates to 'Independent Director 2023 Annual Work Report'. It is a detailed report by an independent director about their duties, attendance at board and committee meetings, communication with auditors, oversight of financial reports, and other governance activities during the year 2023. The content focuses on the independent director's role, responsibilities, and evaluation of company governance and financial reporting. This type of document is a management report detailing the independent director's activities and oversight, which fits best under the category of Management Reports (MDA). It is not an annual report (10-K), audit report (AR), or a simple announcement. The length and detail confirm it is a substantive report, not just an announcement or certification. Therefore, the correct classification is MDA with high confidence.
2024-03-29 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 5th Board of Directors of Tianjin Ruipu Biotechnology Co., Ltd. It includes approvals of various reports such as the 2023 Annual Board Work Report, 2023 Financial Statements, 2023 Audited Financial Report, 2023 Annual Report and Summary, Profit Distribution Plan, Fund Usage Report, Internal Control Self-Evaluation Report, ESG Report, and other related matters. The document repeatedly states that these reports have been or will be disclosed on the Shenzhen Stock Exchange and other official websites, indicating that this document itself is not the full annual report or financial statements but a board meeting resolution announcement. It also mentions that these matters will be submitted to the 2023 Annual General Meeting for approval. The document is over 5,000 characters and contains substantive content about board decisions but does not contain the full financial statements or detailed report content itself. Therefore, it is best classified as Board/Management Information (MANG) because it announces board meeting resolutions and management decisions rather than the full annual report or audit report. Confidence is high given the detailed nature and content of the document.
2024-03-29 Chinese
监事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th meeting of the 5th Supervisory Board of Tianjin Ruipu Biotechnology Co., Ltd. It includes multiple agenda items related to the approval of various reports and proposals such as the 2023 Supervisory Board Work Report, 2023 Financial Final Accounts Report, 2023 Audited Financial Report, 2023 Annual Report and its summary, profit distribution plan, special reports on fund usage, internal control self-assessment, related party transactions, reappointment of the audit firm, and other corporate matters. Each item references the actual reports being disclosed separately on the Shenzhen Stock Exchange and CNINFO websites, indicating that this document itself is not the full reports but a formal announcement of the Supervisory Board's resolutions regarding these reports and proposals. The document is about the meeting resolutions and their approval, which is typical of a Board/Management Information filing. It is not the full Annual Report (10-K), Audit Report (AR), or other detailed financial reports themselves, but rather the Supervisory Board's meeting decisions and approvals. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4893 characters) and content support this classification with high confidence.
2024-03-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.